Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28129 | 213 | 32.4 | 80% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
315 | 3 | ALLERGY//MAST CELLS//BRADYKININ | 39886 |
1331 | 2 | ALLERGIC RHINITIS//ANTIHISTAMINES//ALLERGIC CONJUNCTIVITIS | 8385 |
28129 | 1 | TRANILAST//2 2 PHENOXYACETAMIDOBENZAMIDES//2 2E 3 PHENYLPROP 2 ENOYLAMINOBENZAMIDES | 213 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TRANILAST | authKW | 8515427 | 46% | 60% | 99 |
2 | 2 2 PHENOXYACETAMIDOBENZAMIDES | authKW | 143359 | 0% | 100% | 1 |
3 | 2 2E 3 PHENYLPROP 2 ENOYLAMINOBENZAMIDES | authKW | 143359 | 0% | 100% | 1 |
4 | 2 3 PHENYLPROPANAMIDOBENZAMIDES | authKW | 143359 | 0% | 100% | 1 |
5 | 2 3 PHENYLPROPIOLAMIDOBENZAMIDES | authKW | 143359 | 0% | 100% | 1 |
6 | 2 CINNAMAMIDOBENZAMIDES | authKW | 143359 | 0% | 100% | 1 |
7 | ABEON KU | address | 143359 | 0% | 100% | 1 |
8 | AND TGF BETA | authKW | 143359 | 0% | 100% | 1 |
9 | AZOPRENYLATED SECONDARY METABOLITES | authKW | 143359 | 0% | 100% | 1 |
10 | BRITTLE MAIN COMPOSITES | authKW | 143359 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 673 | 34% | 0% | 72 |
2 | Urology & Nephrology | 134 | 8% | 0% | 17 |
3 | Peripheral Vascular Diseases | 132 | 8% | 0% | 17 |
4 | Cardiac & Cardiovascular System | 129 | 11% | 0% | 23 |
5 | Chemistry, Medicinal | 70 | 6% | 0% | 13 |
6 | Transplantation | 41 | 3% | 0% | 7 |
7 | Ophthalmology | 38 | 4% | 0% | 9 |
8 | Allergy | 27 | 2% | 0% | 4 |
9 | Dermatology | 19 | 3% | 0% | 6 |
10 | Oncology | 19 | 7% | 0% | 15 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ABEON KU | 143359 | 0% | 100% | 1 |
2 | HLTH WELF MITA HOSP | 71678 | 0% | 50% | 1 |
3 | THORAC BREAST ENDOCRINE SURG | 71678 | 0% | 50% | 1 |
4 | LIVINGSTON REPROD BIOL S | 71676 | 1% | 25% | 2 |
5 | EMERY STN EAST | 47785 | 0% | 33% | 1 |
6 | UNIT REGENERAT MED BIOMED TECHNOL | 47785 | 0% | 33% | 1 |
7 | CELL BIOLMINAMI KU | 35838 | 0% | 25% | 1 |
8 | IMMUNE MONITORING UNIT | 35838 | 0% | 25% | 1 |
9 | SERV FARM CLIN | 35838 | 0% | 25% | 1 |
10 | VCU MOL GENET | 35838 | 0% | 25% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JAPANESE JOURNAL OF PHARMACOLOGY | 3264 | 5% | 0% | 10 |
2 | CURRENT EYE RESEARCH | 710 | 2% | 0% | 5 |
3 | INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 632 | 1% | 0% | 3 |
4 | EUROPEAN JOURNAL OF PHARMACOLOGY | 497 | 5% | 0% | 10 |
5 | ATHEROSCLEROSIS | 478 | 3% | 0% | 6 |
6 | BRITISH JOURNAL OF PHARMACOLOGY | 386 | 3% | 0% | 7 |
7 | MATERIALS SCIENCE RESEARCH INTERNATIONAL | 381 | 0% | 0% | 1 |
8 | JOURNAL OF COSMETIC DERMATOLOGY | 356 | 0% | 0% | 1 |
9 | JOURNAL OF PHARMACOBIO-DYNAMICS | 348 | 1% | 0% | 2 |
10 | TARGETED ONCOLOGY | 345 | 0% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DARAKHSHAN, S , POUR, AB , (2015) TRANILAST: A REVIEW OF ITS THERAPEUTIC APPLICATIONS.PHARMACOLOGICAL RESEARCH. VOL. 91. ISSUE . P. 15 -28 | 107 | 65% | 8 |
2 | ROGOSNITZKY, M , DANKS, R , KARDASH, E , (2012) THERAPEUTIC POTENTIAL OF TRANILAST, AN ANTI-ALLERGY DRUG, IN PROLIFERATIVE DISORDERS.ANTICANCER RESEARCH. VOL. 32. ISSUE 7. P. 2471-2478 | 23 | 82% | 20 |
3 | ISAJI, M , MIYATA, H , AJISAWA, Y , (1998) TRANILAST: A NEW APPLICATION IN THE CARDIOVASCULAR FIELD AS AN ANTIPROLIFERATIVE DRUG.CARDIOVASCULAR DRUG REVIEWS. VOL. 16. ISSUE 3. P. 288 -299 | 32 | 91% | 19 |
4 | KUBO, M , ZHAO, Y , MORIGUCHI, T , (2012) TRANILAST INHIBITS THE CELL GROWTH OF NORMAL HUMAN KERATINOCYTES IN VITRO.ARCHIVES OF DERMATOLOGICAL RESEARCH. VOL. 304. ISSUE 9. P. 745-753 | 13 | 54% | 0 |
5 | ISLAM, MS , PROTIC, O , CIAVATTINI, A , GIANNUBILO, SR , TRANQUILLI, AL , CATHERINO, WH , CASTELLUCCI, M , CIARMELA, P , (2014) TRANILAST, AN ORALLY ACTIVE ANTIALLERGIC COMPOUND, INHIBITS EXTRACELLULAR MATRIX PRODUCTION IN HUMAN UTERINE LEIOMYOMA AND MYOMETRIAL CELLS.FERTILITY AND STERILITY. VOL. 102. ISSUE 2. P. 597 -606 | 20 | 32% | 2 |
6 | PRUD'HOMME, GJ , (2007) PATHOBIOLOGY OF TRANSFORMING GROWTH FACTOR BETA IN CANCER, FIBROSIS AND IMMUNOLOGIC DISEASE, AND THERAPEUTIC CONSIDERATIONS.LABORATORY INVESTIGATION. VOL. 87. ISSUE 11. P. 1077-1091 | 29 | 19% | 169 |
7 | WATANABE, S , MATSUDA, A , SUZUKI, Y , KONDO, K , IKEDA, Y , HASHIMOTO, H , UMEMURA, K , (2000) INHIBITORY MECHANISM OF TRANILAST IN HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS PROLIFERATION, DUE TO BLOCKADE OF PDGF-BB-RECEPTORS.BRITISH JOURNAL OF PHARMACOLOGY. VOL. 130. ISSUE 2. P. 307 -314 | 18 | 49% | 13 |
8 | CAPPER, EA , ROSHAK, AK , BOLOGNESE, BJ , PODOLIN, PL , SMITH, T , DEWITT, DL , ANDERSON, KM , MARSHALL, LA , (2000) MODULATION OF HUMAN MONOCYTE ACTIVITIES BY TRANILAST, SB 252218, A COMPOUND DEMONSTRATING EFFICACY IN RESTENOSIS.JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. VOL. 295. ISSUE 3. P. 1061-1069 | 17 | 50% | 24 |
9 | SEE, F , WATANABE, M , KOMPA, AR , WANG, BH , BOYLE, AJ , KELLY, DJ , GILBERT, RE , KRUM, H , (2013) EARLY AND DELAYED TRANILAST TREATMENT REDUCES PATHOLOGICAL FIBROSIS FOLLOWING MYOCARDIAL INFARCTION.HEART LUNG AND CIRCULATION. VOL. 22. ISSUE 2. P. 122-132 | 14 | 42% | 4 |
10 | SAID, E , ELKASHEF, WF , ABDELAZIZ, RR , (2016) TRANILAST AMELIORATES CYCLOPHOSPHAMIDE-INDUCED LUNG INJURY AND NEPHROTOXICITY.CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY. VOL. 94. ISSUE 4. P. 347 -358 | 14 | 38% | 0 |
Classes with closest relation at Level 1 |